A university professor on your founding team looks like an asset. Real technical depth, academic credibility, a name investors recognize.
I pass on the investment.[1] That professor will keep inventing in your field, and the university owns everything they invent. Those are the inventions your company needs, and no agreement the founders sign changes who owns them. The monster was there before your company existed, and nobody tames it.
The Incentive Mismatch
A professor’s career is measured in published papers. Tenure committees, grant reviewers, and department chairs count papers and citations. None of them count products or revenue.
Your company needs to own all the downstream improvements. Those are the valuable patents. The professor publishes to keep a career, and every result of that work is a roadblock to your expansion and a ceiling on your own product. The university owns it. Your company does not.
The University Owns Your Roadmap
Assume the best case for your company. You own the original patent outright, with no ownership dispute and no gap in the paperwork.[2] The monster is still there, and it blocks every direction you want to grow.
Most research universities require faculty to assign their inventions to the university as a condition of employment. This is standard practice rather than a hidden trap. Universities fund labs, equipment, and graduate students partly through licensing revenue, and the assignment clause is how that funding model works. That same professor also owes the university new research every year, and tenure review does not pause because the professor spent a year helping a startup.
To make a professor useful to your team, you have to explain the technology. All of it. The architecture, the design choices, the problems you have not solved, and where the product goes in three years. By the time that person can contribute, they understand your roadmap as well as anyone at your company.
Then they go back to the lab, where the job is to produce new work and publish it. The obvious place to start is the field they just spent months learning. They find a faster method, a cheaper material, an application in a market you have not entered yet. Good researchers do good research in the field they know best.
The university owns every bit of it.
Now look at what your company can build. You own the original patent, so no competitor can copy the original technology. The university owns the improvement, so you cannot build the improvement. Your own next-generation product sits behind someone else’s patent, and the market you planned to enter sits behind a second patent.[3] You can pay the university for a license on whatever terms it names, or you can watch a competitor pay for it instead.[4]
A technology transfer office understands this perfectly. A patent that blocks a funded company is the most valuable thing that office can own. The professor who knows your roadmap is the person best positioned to produce one. Nothing about that is accidental. Every incentive that office has aims at the ground your company needs next.
None of this requires bad faith from anyone. The professor publishes, develops new work, and honors an agreement signed years before your company existed. The conflict is structural, not personal, and the professor created neither side of it.
Your company did. You explained the technology, funded the collaboration, and aimed the best researcher you could find straight down your own roadmap. Everything after that is the arrangement working as designed. You created a monster, and you created it by doing everything a good founder is supposed to do.
When the University Comes After It
Founders sometimes assume the professor can fix this by resigning. Most invention-assignment agreements use present-tense language: the professor “hereby assigns” the university every invention conceived or reduced to practice while employed, using university resources, or arising from university-sponsored research.[5] The assignment happened the moment the invention was conceived, and a resignation letter does not undo it. Many agreements add a holdover clause on top of that. For six months to a year after the professor leaves, anything they invent that touches the earlier university work still belongs to the university.[6]
The university rarely moves while the technology is still speculative. A technology transfer office has no reason to spend money on something that might never be worth anything. Once the technology proves valuable, the university comes after what it has owned all along.
John Fenn developed electrospray ionization mass spectrometry while on the Yale faculty in the late 1980s. He got the patent in his own name, told nobody at Yale, and kept the royalties. In 2002 the work won him a share of the Nobel Prize in Chemistry. Yale sued. A federal court found Fenn had committed fraud, ordered the patent reassigned, and made him pay Yale more than a million dollars in damages and legal fees.[7] Yale owned that invention from the day Fenn conceived it in a Yale lab, and Yale left it alone for years. The Nobel Prize is what moved Yale to act.
The pattern does not need a famous name. The University of Missouri sued a chemical engineering professor and a postdoctoral fellow over patents the professor allegedly kept by altering the university’s invention-disclosure paperwork.[8] The University of Missouri-Kansas City accused a professor of taking a graduate student’s pharmaceutical research and selling it to a company for more than a million dollars.[9] In both cases the university moved once real money was on the table.
Why the University Has Nothing to Lose
Three things make this worse than an ordinary lawsuit risk, and none of them depend on the particular case.
A university walks into court wearing the white hat. A company suing over a patent reads as a business protecting its bottom line. A university suing over the same patent reads as an educational institution recovering what its research mission was owed. The advantage is real, though it is not immunity. Universities have drawn public criticism of their own for enforcement that looks commercial.[10]
The litigation costs the university very little. Law firms have grown more reluctant to take patent cases on pure contingency, because patent litigation is expensive and uncertain even when the underlying case is strong.[11] Universities reach for third-party litigation funding instead, or assign the patent to a separate entity created to bring the suit.[12] Either route keeps the fight off the university’s operating budget. Your company weighs every dollar of a defense. The university does not.
The university does not even need to win. The Wisconsin Alumni Research Foundation sued Apple over a patent on processor efficiency, won $234 million at trial in 2015, and lost the verdict on appeal in 2018.[13] Years of litigation against one of the largest companies in the world, and the foundation collected nothing. Every researcher and technology transfer office watching learned one thing. The university sued Apple and took the case all the way to trial. That message costs nothing to send and it never expires.
The Takeaway
Walk away from this structure. A company can own its original patent, sign every agreement correctly, and still spend the next ten years watching the university take ownership of every improvement the company needs next. No side letter or founder agreement prevents that, because the improvements do not exist yet. The person best positioned to invent them spends every working day contractually obligated to hand them to someone else.
None of this happened to careless founders. Yale owned Fenn’s invention from the moment he conceived it, then waited until a Nobel Prize made the fight worth having. Success never decided who owned the work. Success decided when the university acted.
Other co-founders can do this work. Other ideas come with no university attached. A company built on a professor’s ongoing academic work has staked its core asset on a contract signed years earlier, with an employer that collects the upside. Find the co-founder, or the idea, your company can own outright.
Do not build your core technology around a sitting faculty member’s lab. Every improvement that lab produces belongs to the university, and your growth depends on exactly those improvements.
Sources
1 Risks of Investing in Government-Sponsored Research applies the same investment posture to the adjacent case: patents built on federally funded research carry government march-in rights under 37 CFR 401.6, letting a bureaucrat with no entrepreneurial background decide that commercialization has been insufficient and take the patent back, with no judicial review and no compensation to the investor who funded the company on the strength of it. ↩
2 Who Owns the Invention? explains why clean ownership is worth assuming as a best case rather than a given: in the United States an invention belongs to the inventor personally until assigned in writing, each of several inventors holds full independent rights, and many startups never put the basic agreements in place. Lenders stop the diligence the moment clear title is missing, and an inventor holding an issued patent has enough leverage to make a retroactive assignment expensive or impossible. ↩
3 “We Own This Space” Is the Wrong Way to Think About Your Patents makes the same structural point about what a patent does and does not buy: a patent is the right to exclude one specific thing, not a deed to a market, and a company’s own patent can itself be blocked by someone else’s patent covering that company’s product. ↩
4 Exclusive Licenses Can Be More Valuable Than Owning Patents Outright argues that a license is often the better instrument than ownership, with one blunt caveat directly relevant here: most university technology transfer offices are poor at licensing, misunderstanding what a startup needs and carrying internal incentives that discourage closing a deal at all. ↩
5 Understanding Pre-Invention Assignment Agreements (Nolo) describes the present-tense “hereby assigns” language that makes assignment automatic at the moment of conception, rather than at some later formal transfer. ↩
6 Employee Assignments of Inventions — An Update (Fennemore) discusses post-employment holdover clauses, generally enforceable for a limited period (commonly six months to a year) and limited to inventions related to the work done for the former employer. ↩
7 Yale Wins Suit Against Nobel Laureate (Science/AAAS, 2005) covers the outcome of Fenn v. Yale University, in which a federal court found Nobel laureate John Fenn had defrauded Yale of a patent he was contractually obligated to assign, ordering the patent reassigned and damages paid. ↩
8 University Sues Prof in Patent Dispute (Courthouse News Service) covers the University of Missouri’s suit against a chemical engineering professor and postdoctoral fellow over altered invention-disclosure paperwork. ↩
9 Ex-Missouri University Professor Accused of Stealing Student’s Invention, Making Millions (NBC News) covers the University of Missouri-Kansas City dispute over a graduate student’s research sold to a pharmaceutical company. ↩
10 Mark A. Lemley, “Are Universities Patent Trolls?” Fordham Intellectual Property, Media & Entertainment Law Journal, and “Patent Infringement Suits Have a Reputational Cost for Universities” (Brookings) both document the reputational debate over aggressive university patent enforcement, and the real cost that debate creates even for a nonprofit patent holder. ↩
11 “Contingency Fees Make Patent Enforcement Accessible” (Law360) notes that fewer law firms take university patent cases on pure contingency because of the cost and risk specific to patent litigation. ↩
12 Litigation Funding for Universities and Technology Transfer Offices (Woodsford) and the U.S. Government Accountability Office’s Information on Third-Party Funding of Patent Litigation describe the litigation-funding and patent-assignment structures universities use to pursue enforcement without funding it from their own operating budget. ↩
13 WARF Wins Patent Infringement Lawsuit Against Apple (University of Wisconsin-Madison, 2015) and the Federal Circuit’s 2018 opinion reversing the verdict cover the Wisconsin Alumni Research Foundation’s litigation against Apple. ↩
